Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Update

Adaptimmune Therapeutics plc (NASDAQ:ADAP) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 3,410,000 shares, a growth of 6.6% from the March 31st total of 3,200,000 shares. Based on an average daily trading volume, of 1,970,000 shares, the days-to-cover ratio is presently 1.7 days.

Adaptimmune Therapeutics Price Performance

Shares of ADAP opened at $1.19 on Wednesday. The firm has a market capitalization of $293.72 million, a PE ratio of -2.16 and a beta of 2.39. Adaptimmune Therapeutics has a 1-year low of $0.42 and a 1-year high of $2.05. The company’s fifty day moving average price is $1.38 and its 200-day moving average price is $0.94.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings results on Wednesday, March 6th. The biotechnology company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.12). Adaptimmune Therapeutics had a negative net margin of 188.90% and a negative return on equity of 155.39%. The business had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $4.80 million. As a group, research analysts anticipate that Adaptimmune Therapeutics will post -0.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Acuitas Investments LLC purchased a new stake in Adaptimmune Therapeutics in the third quarter valued at $374,000. Key Client Fiduciary Advisors LLC boosted its holdings in Adaptimmune Therapeutics by 6.4% in the fourth quarter. Key Client Fiduciary Advisors LLC now owns 336,620 shares of the biotechnology company’s stock valued at $267,000 after purchasing an additional 20,295 shares during the last quarter. Harbor Capital Advisors Inc. boosted its holdings in Adaptimmune Therapeutics by 9.9% in the fourth quarter. Harbor Capital Advisors Inc. now owns 147,732 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 13,317 shares during the last quarter. Marquette Asset Management LLC purchased a new stake in shares of Adaptimmune Therapeutics during the 3rd quarter worth about $77,000. Finally, Twin Focus Capital Partners LLC purchased a new stake in shares of Adaptimmune Therapeutics during the 4th quarter worth about $44,000. 31.37% of the stock is owned by hedge funds and other institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.